Canopy Slaps GW With Patent Suit Over Flagship CBD Drug
By Diana Novak Jones (December 23, 2020, 1:28 PM EST) -- Canadian cannabis company Canopy Growth is accusing GW Pharmaceuticals of ripping off its patented CBD extraction technology to make the flagship CBD drug Epidiolex.
GW knows its method for making Epidiolex, the first pharmaceutical derived from marijuana to be approved by the U.S. Food and Drug Administration, copies Canopy's patented technique for extracting THC and CBD from cannabis plants, Canopy said in Tuesday's complaint.
Epidiolex is the U.K.-based GW's primary product, bringing in $366 million in the first nine months of this year, the suit claims. It was approved by the FDA in 2018 and is used to treat specific seizure...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!